Health Care Equipment

Senseonics

Senseonics released FY2026 Q1 earnings on May 7 After-Market EST, actual revenue USD 11.71 M (forecast USD 9.826 M), actual EPS USD -0.7099 (forecast USD -0.69)

Senseonics to Release FY2026 Q1 Earnings on May 7 After-Market EST, Forecast Revenue USD 9.826 M, EPS USD -0.67

Senseonics released FY2025 Q4 earnings on March 2 After-Market EST, actual revenue USD 14.26 M (forecast USD 14.2 M), actual EPS USD -0.4642 (forecast USD -0.4216)

Senseonics released FY2025 earnings on March 2 After-Market EST: Actual Revenue USD 0 (Forecast USD 35.2 M), Actual EPS USD 0 (Forecast USD -1.5016)

Senseonics to Release FY2025 Q4 Earnings on March 2, After-Market EST; Forecast Revenue USD 14.2 M, EPS USD -0.4216

Jonathan Block Maintains Senseonics Holdings at Hold, With a Price Target of $9.00

Senseonics released FY2025 Q3 earnings on November 5 After-Market (EST), actual revenue USD 8.095M (forecast USD 7.973M), actual EPS USD -0.4344 (forecast USD -0.305)

Senseonics released FY2025 9 Months Earnings on November 5 After-Market EST, with actual revenue of USD 21M and EPS of USD -1.2344

Senseonics to Release FY2025 Q3 Earnings on November 5 After-Market EST, Forecast Revenue USD 7.924 M, EPS USD -0.305

Block Reiterates Hold Rating on Senseonics Holdings

Senseonics released FY2025 Semi-Annual earnings on August 6 After-Market EST, actual revenue USD 12.91 M, actual EPS USD -0.7999

Senseonics released FY2025 Q2 earnings on August 6 After-Market (EST), actual revenue USD 6.649 M (forecast USD 6.022 M), actual EPS USD -0.4 (forecast USD -0.4)

Senseonics to release FY2025 Q2 earnings on August 6 After-Market EST, forecast revenue USD 6.022 M, EPS USD -0.02

TD Cowen Issues 'Buy' Rating on Senseonics Stock

Senseonics Holdings to Host Analyst Event

Senseonics Holdings Announces Successful Annual Shareholders Meeting

Senseonics Announces Company Updates

Senseonics Holdings Announces $50 Million Public Offering

Senseonics released FY2025 Q1 earnings on May 8 After-Market (EST), actual revenue USD 6.257 M (forecast USD 5.558 M), actual EPS USD -0.4 (forecast USD -0.4666)

Senseonics to release FY2025 Q1 earnings on May 8 After-Market EST, forecast revenue USD 5.566 M, EPS USD -0.025

Freecast

Cuprina

U-BX Tech

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Defiance Pure Space Dly 2X Strat ETF

VS MEDIA

Everbright Digital

Park Ha Biological Tech

Friedman Industries

Defiance Daily Target 2X Short ASTS ETF

SENS

Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems | SENS Stock News

StockTitan

Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems | SENS Stock News

AGEN

OCGN

NKTR

CTMX

VTHR

SBIO

FTSE Russell has announced preliminary changes to the Russell 3000 Index, adding several healthcare stocks including Ocugen, Senseonics, Nektar Therapeutics, Agenus, and CytomX Therapeutics. These additions can enhance visibility and attract investment from ETFs. Ocugen has surged over 140% in the past year, while Nektar Therapeutics has jumped over 250%. Analysts rate these stocks favorably, with Ocugen showing the highest upside potential at over 760%.

Tip Ranks

Agenus

Ocugen

Nektar Therap

Cytomx Therap

Vanguard Russell 3000

ALPS Medical Breakthrough

ISHRS Russ 3000

Health Care Select Sector SPDR

iBio

Assertio

AGENUS INC

5 Healthcare Stocks Set to Join the Russell 3000

Senseonics Holdings Inc. reported strong Q1 2026 earnings, with net revenue rising 85% to $11.7 million, driven by the Eversense 365 sensor. Gross margin improved to 58%, and the company raised its full-year revenue outlook to $60-$64 million. Despite a net loss of $32.3 million due to high operating expenses, management remains optimistic about growth, citing successful U.S. commercial integration and a doubling of direct-to-consumer shipments. The company also expanded its credit facility and raised $92 million in equity to support its growth initiatives.

iShares US Medical Devices

SPDR S&P Health Equip

Senseonics Earnings Call Highlights Rapid Growth Push

Earnings Watch

Senseonics | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 11.71 M

LABU

Senseonics Holdings, Inc. (NASDAQ:SENS) has received an average recommendation of "Moderate Buy" from six research firms. The stock has one sell, one hold, three buy, and one strong buy rating. The average target price is $18.3750. Recent insider transactions include CEO Timothy T. Goodnow acquiring 17,225 shares and Director Douglas A. Roeder acquiring 17,500 shares. Institutional investors have also increased their stakes significantly. The stock opened at $5.10, with a market cap of $213.13 million and a 52-week range of $4.96 to $15.20.

Market Beat

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Stifel Financial

Toronto Dominion Bank

UBS Group AG

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Given Average Recommendation of "Moderate Buy" by Brokerages

Senseonics shares fell 24% to $5.04 following the announcement of its underwritten public offering priced at $5 per share. The company plans to offer 8 million shares and 8 million pre-funded warrants, expecting to raise $80 million. The stock has lost 9% of its value this year, hitting a 52-week low of $4.96. The offering is set to close on May 4, with underwriters granted a 30-day option to purchase an additional 2.4 million shares.

MorningStar

Senseonic Shares Slide on Underwritten Offering Price

Senseonics(SENS.US)

Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems | SENS Stock News

5 Healthcare Stocks Set to Join the Russell 3000

Senseonics Earnings Call Highlights Rapid Growth Push

Senseonics | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 11.71 M

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Given Average Recommendation of "Moderate Buy" by Brokerages

Senseonic Shares Slide on Underwritten Offering Price